Drug Application
Comparison of efficacy of glipizide versus repaglinide in the treatment of type 2 diabetes mellitus
Li Yanping
Published 2021-12-10
Cite as Chin J Pract Med, 2021, 48(23): 94-97. DOI: 10.3760/cma.j.cn115689-20210714-02313
Abstract
ObjectiveTo compare the clinical effects of glipizide and repaglinide on type 2 diabetes mellitus.
MethodsA total of 108 patients with type 2 diabetes mellitus admitted to Shuozhou Central Hospital from January 2018 to December 2019 were randomly divided into two groups, with 54 cases in each group. The control group was treated with glipizide, and the observation group was treated with repaglinide. After 6 months of treatment, the therapeutic effects of the two groups were evaluated, and blood glucose, lipid indexes, efficacy and adverse effects were compared between the two groups before and after treatment.
ResultsBefore treatment, there was no difference in blood glucose indexes or lipid indexes between the two groups (P>0.05). After treatment, the observation group had better improvement in blood glucose indexes and lipid indexes than the control group (P<0.05). The total effective rate of the observation group (98.15%, 53/54) was higher than that of the control group (85.18%, 46/54), P<0.05. There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).
ConclusionsCompared with glipizide, repaglinide can better improve the blood glucose and lipid indexes, and has better curative effects and fewer adverse reactions in the treatment of type 2 diabetes mellitus.
Key words:
Type 2 diabetes mellitus; Glipizide; Repaglinide; Curative effect; Blood glucose index; Blood lipid index
Contributor Information
Li Yanping
Department of Pharmacy, Shuozhou Central Hospital, Shuozhou 036002, China
